Clinical DevelopmentNkarta remains focused on executing NKX019’s clinical development in refractory autoimmune disease.
Financial PerformanceThe company finished the quarter with a cash & equivalents position of $334M, expected to provide operating runway into 2029.
Leadership And ExperienceAppointment of Shawn Rose as Chief Medical Officer and Head of Research and Development, who played a key role in the development of several approved medicines for autoimmune diseases.